Arbutus Biopharma (NASDAQ:ABUS) was downgraded by investment analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued to investors on Monday. They presently have a $6.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price target would indicate a potential upside of 17.65% from the company’s previous close.
A number of other research firms also recently commented on ABUS. BidaskClub upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, March 10th. B. Riley started coverage on Arbutus Biopharma in a report on Friday, January 5th. They set a “buy” rating and a $10.00 price objective for the company. Zacks Investment Research downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $12.00.
Shares of Arbutus Biopharma stock opened at $5.10 on Monday. The company has a market capitalization of $289.12, a price-to-earnings ratio of -3.39 and a beta of 1.02. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a twelve month low of $2.95 and a twelve month high of $8.25.
Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.51). The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $0.70 million. Arbutus Biopharma had a negative return on equity of 51.80% and a negative net margin of 796.23%. research analysts predict that Arbutus Biopharma will post -1.63 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in ABUS. Spark Investment Management LLC increased its holdings in Arbutus Biopharma by 98.3% in the 4th quarter. Spark Investment Management LLC now owns 23,000 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 11,400 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Arbutus Biopharma in the 4th quarter valued at $146,000. Two Sigma Investments LP acquired a new stake in Arbutus Biopharma in the 4th quarter valued at $215,000. Goldman Sachs Group Inc. acquired a new stake in Arbutus Biopharma in the 4th quarter valued at $275,000. Finally, Vanguard Group Inc. increased its holdings in Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares in the last quarter. Hedge funds and other institutional investors own 62.14% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Arbutus Biopharma (ABUS) Downgraded by Wedbush” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/19/arbutus-biopharma-abus-downgraded-by-wedbush-to-neutral.html.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.